Long-acting Injectable Antiretroviral Therapy for HIV-1 Infection in Adults

Cutrell A, Schapiro J, Perno C, Kuritzkes D, Quercia R, Patel P . Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis. AIDS. 2021; 35(9):1333-1342. PMC: 8270504. DOI: 10.1097/QAD.0000000000002883. View

Scarsi K, Swindells S . The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data?. J Int Assoc Provid AIDS Care. 2021; 20:23259582211009011. PMC: 8082990. DOI: 10.1177/23259582211009011. View

Orkin C, Bernal Morell E, Tan D, Katner H, Stellbrink H, Belonosova E . Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. Lancet HIV. 2021; 8(11):e668-e678. DOI: 10.1016/S2352-3018(21)00184-3. View

Overton E, Richmond G, Rizzardini G, Thalme A, Girard P, Wong A . Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study. Clin Infect Dis. 2023; 76(9):1646-1654. PMC: 10156123. DOI: 10.1093/cid/ciad020. View